Visible weight loss begins within 3-4 weeks, with most patients losing 5-10 lbs in the first month
Overall gastrointestinal adverse event rates Across the STEP trials, 72.9% of participants receiving semaglutide 2.4 mg reported at least one gastrointestinal adverse event, compared to 47.1% on placebo
A study published in Diabetes Obes Metab showed that semaglutide resulted in over a decade of greater reduction of body weight than placebo, lifestyle modification or pharmacotherapy with orlistat after 68 weeks of treatment
This triple-hit strategy implies that retatrutide might work swifter or superior for certain individuals
This man-made peptide, which has the CAS number 910463-68-2, has sparked a lot of interest in drug studies and clinical uses linked to metabolic diseases
Compounded Semaglutide There's also compounded semaglutide injections